Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

American Heart Journal

Volumn 168, Issue 1, 2014, Pages

  Holman, Rury R ^a   Bethel, Mary A ^a   Chan, Juliana C N ^b   Chiasson, Jean Louis ^c   Doran, Zoë ^a   Ge, Junbo ^d   Gerstein, Hertzel ^e   Huo, Yong ^f   McMurray, John J ^g   Ryden, Lars ^h   Liyanage, Winitha ^a   Schröder, Stefan ⁱ   Tendera, Michal ^j   Theodorakis, Michael J ^a   Tuomilehto, Jaakko ^k,o,p   Yang, Wenying ^l   Hu, Dayi ^m   Pan, Changyu ⁿ  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d FUDAN UNIVERSITY   (China)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f PEKING UNIVERSITY FIRST HOSPITAL   (China)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ BAYER PHARMA AG   (Germany)

^j MEDICAL UNIVERSITY OF SILESIA   (Poland)

^k DANUBE UNIVERSITY KREMS   (Austria)

^l CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^m PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

ⁿ CHINESE PLA GENERAL HOSPITAL   (China)

^o NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^p KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; BLOOD GLUCOSE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; PROSPECTIVE STUDIES; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84902959136     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.03.021     Document Type: Article

References (47)

1. T.A. Pearson, S.N. Blair, and S.R. Daniels et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee Circulation 106 2002 388 391 (Pubitemid 34778969)
2. J. Perk, G. De Backer, and H. Gohlke et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Guidelines on cardiovascular disease prevention in clinical practice Eur Heart J 33 2012 1635 1701
3. Chinese Society of Cardiology of Chinese Medical Association, and Editorial Board of Chinese Journal of Cardiology Chinese guidelines for prevention of cardiovascular diseases Zhonghua Xin Xue Guan Bing Za Zhi 39 2011 3 22
4. P.K. Myint, P.G. Surtees, and N.W. Wainwright et al. Modifiable lifestyle behaviors and functional health in the European Prospective Investigation into Cancer (EPIC) - Norfolk population study Prev Med 44 2007 109 116 (Pubitemid 46186488)
5. DECODE Study Group, and the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria Arch Intern Med 16 2001 397 405
6. F.M. Turnbull, C. Abraira, and R.J. Anderson et al; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2009 2288 2298
7. E. Barrett-Connor, and A. Ferrara Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study Diabetes Care 21 1998 1236 1239 (Pubitemid 28365676)
8. DECODE Study Group, and the European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diab Care 26 2003 688 696
9. A. Ceriello, K. Esposito, and L. Piconi et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients Diabetes 57 2008 1349 1354
10. R. Marfella, G. Verrazzo, and R. Acampora et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects Am J Physiol 268 1995 1167 1173
11. H. Kawano, T. Motoyama, and O. Hirashima et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery J Am Coll Cardiol 34 1999 146 154
12. F. Cosentino, K. Hishikawa, and Z.S. Katusic et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells Circulation 96 1997 25 28 (Pubitemid 27298398)
13. A. Ceriello Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects Diabetologia 36 1993 1119 1125 (Pubitemid 23314561)
14. A. Ceriello, E. Falleti, and E. Motz et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress Horm Metab Res 30 1998 146 149 (Pubitemid 28172522)
15. R. Marfella, K. Esposito, and R. Giunta et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia Circulation 101 2000 2247 2251 (Pubitemid 30317125)
16. K. Esposito, F. Nappo, and R. Marfella et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress Circulation 106 2002 2067 2072 (Pubitemid 35192812)
17. K. Esposito, D. Giugliano, and F. Nappo et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus Circulation 110 2004 214 219 (Pubitemid 38924590)
18. T.C. Wascher, I. Schmoelzer, and A. Wiegratz et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance Eur J Clin Invest 35 2005 551 557 (Pubitemid 41243298)
19. G. Rudofsky Jr., P. Reismann, and S. Schiekofer et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs Horm Metab Res 36 2004 630 638 (Pubitemid 39457641)
20. X. Wang, J. Lu, and C. Pan Comparison of serum C-reactive protein level in different glucose tolerance subjects and the change in serum CRP level in IGT subjects with acarbose [EASD abstract 1634 - Published in Chinese: Lu JM, et al Chin J Endocrinol Metab 19 2003 254 256
21. R.L. Jones, and C.M. Peterson Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon Clin Invest 63 1979 485 493 (Pubitemid 9130212)
22. A. Ceriello, C. Taboga, and L. Tonutti et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose Diabetologia 39 1996 469 473 (Pubitemid 26093875)
23. M. Hanefeld, J.L. Chiasson, and C. Koehler et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance Stroke 35 2004 1073 1078 (Pubitemid 38543520)
24. T. Kato, T. Inoue, and K. Node Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study Cardiovasc Diabetol 9 2010 12
25. Y. Kusunoki, T. Katsuno, and M. Myojin et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin Endocr J 2012 EJ12 0290
26. H.C. Gerstein, S. Yusuf, and J. Bosch et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Lancet 368 2006 1096 1105
27. E.A. Walker, M. Molitch, and M.K. Kramer et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program Diabetes Care 29 2006 1997 2002 (Pubitemid 44871177)
28. J. Lindström, J.G. Eriksson, and T.T. Valle et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial J Am Soc Nephrol 14 2003 S108 S113
29. Q. Gong, E.W. Gregg, and J. Wang et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study Diabetologia 54 2011 300 307
30. R.R. Holman, L. Blackwell, and I.M. Stratton et al. Six-year results from the Early Diabetes Intervention Trial Diabet Med 20 2003 15 [abstract]
31. O.M. Herlihy, R.J. Morris, and S. Karunakaran et al. Sulphonylurea therapy over six years does Not delay progression to diabetes Diabetologia 43 2000 A73 [Abstract]
32. R.A. DeFronzo, D. Tripathy, and D.C. Schwenke et al. Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 364 2011 1104 1115
33. B. Zinman, S.B. Harris, and J. Neuman et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study Lancet 376 2010 103 111
34. L. Jiang, S.M. Manson, and J. Beals et al. Translating the Diabetes Prevention Program Into American Indian and Alaska Native Communities: Results from the Special Diabetes Program for Indians Diabetes Prevention Demonstration Project Diabetes Care 36 2013 2027 2034
35. J.L. Chiasson, R.G. Josse, and R. Gomis et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 2002 2072 2079
36. J.L. Chiasson, R.G. Josse, and R. Gomis et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494 (Pubitemid 37430502)
37. M. Hanefeld, M. Cagatay, and T. Petrowitsch et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 25 2004 10 16 (Pubitemid 38055587)
38. R.R. Holman, S.M. Haffner, and J.J. McMurray et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1463 1476
39. H.C. Gerstein, J. Bosch, and G.R. Dagenais et al; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 367 2012 319 328
40. L. Rydén, E. Standl, and M. Bartnik et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136 (Pubitemid 46137814)
41. K. Thygesen, J.S. Alpert, and A.S. Jaffe et al. Third universal definition of myocardial infarction Eur Heart J 33 2012 2551 2567
42. H. Li, X. Zhang, and G. Xu et al. Determination of reference intervals for creatinine and evaluation of creatinine-based estimating equation for Chinese patients with chronic kidney disease Clin Chim Acta 403 2009 87 91
43. Chen Shao-liang, Ye Fei, and Zhang Jun-Jie et al. Comparison of a five-year clinical outcome between Chinese women and men with de novo coronary disease treated with implantation of a drug-eluting stent: a three-center, prospective, registry study Chin Med J 125 2012 7 11
44. D.R. Cox, and E.J. Snell Analysis of binary data 2nd ed. 1989 Chapman and Hall London
45. B.M. Psaty, and D. Rennie Stopping medical research to save money: a broken pact with researchers and patients JAMA 289 2003 2128 2131 (Pubitemid 37430215)
46. J.L. Chiasson, R. Gomis, and M. Hanefeld et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus Diabetes Care 21 1998 1720 1735
47. D.Y. Hu, C.Y. Pan, and J.M. Yu et al. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey Eur Heart J 27 2006 2573 2579